Literature DB >> 30737793

Call for improved design and reporting in soft tissue sarcoma studies: A systematic review and meta-analysis of chemotherapy and survival outcomes in resectable STS.

Alexandra C Istl1,2, Jessica M Ruck3, Carol D Morris4, Adam S Levin4, Christian F Meyer5, Fabian M Johnston3,6.   

Abstract

New evidence and systemic therapies demand an updated analysis of chemotherapy for soft tissue sarcoma. We completed a meta-analysis of chemotherapy in localized STS, assessing OS, PFS, and local and distant recurrence (local recurrence-free survival [LRFS] and distant recurrence-free survival [DRFS]). Ten studies, totaling 3157 patients, were included. A pooled analysis for 5-year OS, progression-free survival, LRFS, and DRFS showed no benefit of chemotherapy over locoregional therapy alone for all-comers or site-specific STS. We make recommendations to improve outcome reporting and quality indices.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  chemotherapy; localized; resectable; soft tissue sarcoma

Mesh:

Year:  2019        PMID: 30737793     DOI: 10.1002/jso.25401

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  2 in total

Review 1.  Neoadjuvant Therapy for Primary Resectable Retroperitoneal Sarcomas-Looking Forward.

Authors:  Alexandra C Istl; Alessandro Gronchi
Journal:  Cancers (Basel)       Date:  2022-04-05       Impact factor: 6.639

2.  Identification of Tumor Antigens and Immune Subtypes for the Development of mRNA Vaccines and Individualized Immunotherapy in Soft Tissue Sarcoma.

Authors:  Changwu Wu; Yingjuan Duan; Siming Gong; Georg Osterhoff; Sonja Kallendrusch; Nikolas Schopow
Journal:  Cancers (Basel)       Date:  2022-01-17       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.